United States — United States Securities and Exchange Commission & Leerink Partners
12 shared events · Importance 4 · Last updated Aug 07, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States — United States Securities and Exchange Commission: The SEC declared the registration statement effective, enabling the IPO to proceed, fulfilling its regulatory oversight role.
Leerink Partners: Leerink Partners served as joint book-running manager, benefiting from underwriting fees and strengthening its healthcare franchise.
Aug 05, 2026 · 15 articles
Business
United States — United States Securities and Exchange Commission: The SEC declared the registration statements effective, enabling the IPO to proceed. This regulatory action is routine but essential for the offering's completion.
Leerink Partners: Leerink Partners served as a lead book-running manager, generating underwriting revenue and reinforcing its expertise in healthcare IPOs. The deal enhances its reputation in the sector.
Aug 07, 2026 · 8 articles
Business
United States — United States Securities and Exchange Commission: The United States — United States Securities and Exchange Commission declared the registration statement for Amanat Acquisition Corporation's IPO effective, overseeing the regulatory compliance of the offering.
Leerink Partners: Leerink Partners is acting as the sole bookrunning manager for Amanat Acquisition Corporation's IPO, responsible for managing the offering.
May 19, 2026 · 6 articles
Business
United States — United States Securities and Exchange Commission: The SEC reviewed and declared effective Scribe's registration statement, enabling the IPO. Its regulatory oversight is a standard part of the process.
Leerink Partners: Leerink Partners acted as a joint book-running manager for the IPO, earning fees and enhancing its reputation in biotech capital markets.
Jul 06, 2026 · 25 articles
Business
United States — United States Securities and Exchange Commission: The SEC oversees the registration and prospectus filing for the offering, ensuring regulatory compliance.
Leerink Partners: Leerink Partners is a joint book-running manager, participating in the offering and earning fees.
Aug 04, 2026 · 6 articles
Business
United States — United States Securities and Exchange Commission: The United States — United States Securities and Exchange Commission is the regulatory body with which Tango Therapeutics filed its shelf registration statement and related prospectus documents for the offering.
Leerink Partners: Leerink Partners is acting as a joint bookrunning manager for the public offering by Tango Therapeutics, assisting in the sale of securities.
Jun 08, 2026 · 8 articles
Business
United States — United States Securities and Exchange Commission: A registration statement for Kailera Therapeutics's IPO was filed with the United States — United States Securities and Exchange Commission and became effective.
Leerink Partners: Leerink Partners acted as a joint book-running manager for Kailera Therapeutics's IPO, facilitating the offering and earning underwriting fees.
Apr 16, 2026 · 8 articles
Business
United States — United States Securities and Exchange Commission: Trevi Therapeutics' offering is being made pursuant to a shelf registration statement filed with the United States — United States Securities and Exchange Commission.
Leerink Partners: Leerink Partners is acting as a joint book-running manager for Trevi Therapeutics' public offering.
Apr 16, 2026 · 7 articles
Business
United States — United States Securities and Exchange Commission: Neurogene filed a shelf registration statement with the United States — United States Securities and Exchange Commission, which was declared effective, enabling the public offering.
Leerink Partners: Leerink Partners is acting as a joint bookrunning manager for Neurogene's public offering.
Jun 30, 2026 · 6 articles
Business
United States — United States Securities and Exchange Commission: The United States — United States Securities and Exchange Commission received registration statements for the offering, ensuring regulatory compliance.
Leerink Partners: Leerink Partners is acting as an active book-running manager for the initial public offering of Parabilis Medicines.
Jun 10, 2026 · 7 articles
Business
Leerink Partners: Leerink Partners served as exclusive financial advisor to Obsidian Therapeutics, Inc. and acted as a placement agent for the private placement financing.
Apr 14, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — United States Securities and Exchange Commission and Leerink Partners interact across events, view sentiment trends, and discover connected entities.
Open Dashboard